56856-73-6

Upstream product

• 99-91-2 para-chloroacetophenone 
• 109-94-4 formic acid ethyl ester 

Downstream Products

• 20739-00-8 7-(4-chloro-phenyl)-pyrido[2,3-d]pyrimidine-2,4-diyldiamine 
• 146201-62-9 bis-[3-(4-chloro-phenyl)-3-oxo-propenyl]-amine 
• 3282-33-5 1-(4-chlorophenyl)-2-diazoethanone 
• 59843-58-2 3-(4-chlorophenyl)-1H-pyrazole 
• 152467-43-1 1-(4-chlorophenyl)-1,3-propanediol 
• 1259429-23-6 3-(4-chlorophenyl)-3-oxopropanal oxime-ethyl ether 
• 339021-13-5 3-(4-chlorophenyl)-3-oxopropanal oxime-methyl ether 
• 170570-91-9 4-[5-(4-chlorophenyl)pyrazol-1-yl]benzenesulfonamide 
• 143620-67-1 C₁₈H₁₆ClNO₃ 
• 91352-43-1 3,3-dimethoxy-1-phenylpropan-1-ol 
• 143631-86-1 1-(4-chlorophenyl)-3-(N-hydroxy-N-benzylamino)-2-propen-1-one 
• 77953-47-0 1,3,3-Trimethyl-2-<3-(p-chlorobenzoyl)-2-propen-1-ylidene>indoline 
• 68047-88-1 [3-(4-chloro-phenyl)-6-methyl-4-(4-nitro-phenyl)-5-oxo-1-phenyl-2,7-dioxa-6-aza-bicyclo[2.2.1]hept-3-yl]-acetaldehyde 

Relevant academic research and scientific papers

Mild acetalisation of mono and dicarbonyl compounds catalysed by titanium tetrachloride. Facile synthesis of β-keto enol ethers

The use of TiCl4, as a catalyst for the acetalisation, at room temperature, of carbonyl compounds is reported. Cyclic ketones and cyclic 1,4-diketones easily afford dimethyl acetals, but cyclic 1,3-diketones give β-keto enol ethers. Additionally, aryl ketones and acyclic ketones failed to react. β-keto aldehydes can be monoprotected either as β-keto enol ethers or β-keto dimethyl acetals depending on the reaction time and catalyst amount. Some mechanistic features are accounted for.

Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies

A method of using pyrazolyl benzenesulfonamide compounds in treating inflammation and inflammation-related disorders in companion animals is disclosed.

Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation

A class of pyrazolyl benzenesulfonamide compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula II: STR1 or a pharmaceutically-acceptable salt thereof.

Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)- 3(trifluoromethyl)-1h-pyrazol-1-yl]benzenesulfonamide (sc-58635, celecoxib)

A series of sulfonamide-containing 1,5-diarylpyrazole derivatives were prepared and evaluated for their ability to block cyclooxygenase-2 (COX-2) in vitro and in vivo. Extensive structure-activity relationship (SAR) work was carried out within this series, and a number of potent and selective inhibitors of COX-2 were identified. Since an early structural lead (1f, SC- 236) exhibited an unacceptably long plasma half-life, a number of pyrazole analogs containing potential metabolic sites were evaluated further in vivo in an effort to identify compounds with acceptable pharmacokinetic profiles. This work led to the identification of 1i (4-[5-(4-methylphenyl)-3- (trifluoromethyl)-1H-pyrazol-1-y1]benzenesulfonamide, SC-58635, celecoxib), which is currently in phase III clinical trials for the treatment of rheumatoid arthritis and osteoarthritis.

Substituted pyrazolyl benzenesulfonamide for the treatment of inflammation

A class of pyrazolyl benzenesulfonamide compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula I: STR1

Synthesis, Chemical, and Biological Properties of Vinylogous Hydroxamic Acids: Dual Inhibitors of 5-Lipoxygenase and IL-1 Biosynthesis

Vinylogous hydroxamic acids (3-N-hydroxy-N-alkylamino)-2-propen-1-ones, VHA) were prepared as antiinflammatory agents.The synthesis, chemical properties, and in vitro biological activities of these relatively unexplored compounds are described.The VHAs were prepared by condensation of the appropriate N-substituted hydroxylamine with any of the three reagents: a 1,3-dicarbonyl compound (method A); a vinylogous amide (method B); or an alkynone (method C).The VHAs exist as one or more tautomers in solution with the relative proportions of each being dependent upon the structure of the VHA, solvent, and pH.VHAs undergo some of the typical reactions of hydroxamic acids as well as those of vinylogous amides.VHAs are active as inhibitors of 5-lipoxygenase and of IL-1 biosynthesis in vitro, which do not inhibit other enzymes of the arachidonic acid cascade.They have been shown by ESR studies to bring about inhibition of soybean type 1 15-lipoxygenase by reduction of the active site iron.